112 related articles for article (PubMed ID: 1295709)
1. Selective immunosuppression with anti-T cell monoclonal antibodies.
Chatenoud L; Bach JF
Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies to CD3 as immunosuppressants.
Chatenoud L; Bach JF
Semin Immunol; 1990 Nov; 2(6):437-47. PubMed ID: 2151769
[TBL] [Abstract][Full Text] [Related]
3. Review and preview of anti-T-cell antibodies.
Helderman JH
Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
[No Abstract] [Full Text] [Related]
4. In vivo T cell activation properties of anti-T cell monoclonal antibodies.
Ferran C; Bach JF; Chatenoud L
Exp Nephrol; 1993; 1(2):83-9. PubMed ID: 8081961
[TBL] [Abstract][Full Text] [Related]
5. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.
Alegre ML; Tso JY; Sattar HA; Smith J; Desalle F; Cole M; Bluestone JA
J Immunol; 1995 Aug; 155(3):1544-55. PubMed ID: 7636216
[TBL] [Abstract][Full Text] [Related]
6. Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.
Li J; Davis J; Bracht M; Carton J; Armstrong J; Gao W; Scallon B; Fung R; Emmell E; Zimmerman M; Griswold DE; Li L
Int Immunopharmacol; 2006 Jun; 6(6):880-91. PubMed ID: 16644473
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in organ transplantation.
Valdés RH
Transplant Proc; 1996 Dec; 28(6):3293. PubMed ID: 8962277
[No Abstract] [Full Text] [Related]
8. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11).
Henrickson M; Reid J; Bellet JS; Sawchuk SS; Hirsch R
Transplantation; 1995 Oct; 60(8):828-35. PubMed ID: 7482743
[TBL] [Abstract][Full Text] [Related]
9. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
10. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
11. The clinical application of monoclonal antibody therapies in renal transplantation.
Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
[TBL] [Abstract][Full Text] [Related]
12. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
13. A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.
Tsuchida M; Brown SA; Tutt LM; Tan J; Seehafer DL; Harris JP; Xun CQ; Thompson JS
Clin Transplant; 1997 Oct; 11(5 Pt 2):522-8. PubMed ID: 9361954
[TBL] [Abstract][Full Text] [Related]
14. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
15. Immunosuppressive effects of anti-CD3 MAb and soluble co-stimulatory molecules.
Bluestone JA; Bruce D; Peterson L; Thistlethwaite JR; Josephson M; Zeng Y; Linsley PS; Lenschow DJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):546-7. PubMed ID: 8438407
[No Abstract] [Full Text] [Related]
16. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3.
Bonnefoy-Berard N; Revillard JP
J Heart Lung Transplant; 1996 May; 15(5):435-42. PubMed ID: 8771497
[TBL] [Abstract][Full Text] [Related]
17. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
18. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
Richards J; Auger J; Peace D; Gale D; Michel J; Koons A; Haverty T; Zivin R; Jolliffe L; Bluestone JA
Cancer Res; 1999 May; 59(9):2096-101. PubMed ID: 10232594
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
20. In vivo immunosuppression induced by a weakly mitogenic antibody to mouse CD3: evidence that induction of long-lasting in vivo unresponsiveness requires TcR signaling.
Flamand V; Donckier V; Abramowicz D; Goldman M; Vandenabeele P; Urbain J; Moser M; Leo O
Cell Immunol; 1994 Aug; 157(1):239-48. PubMed ID: 8039247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
